Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

DelMar Pharmaceuticals raises $5.4mm through private placement post-reverse merger; now totals $10.5mm

Executive Summary

Concurrent with the closing of a reverse merger in which it became public, cancer therapeutics developer DelMar Pharmaceuticals Inc. raised $5.4mm through the first closing of a private placement in which it sold 6.7mm common shares at $0.80 apiece to accredited investors. Buyers also received five-year warrants to purchase 6.7mm additional shares at $0.80. Charles Vista was appointed the placement agent for this and future closings. Proceeds will go towards trials of DelMar’s glioblastoma multiforme candidate VAL083.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies